Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data


13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors.

Thomas Kaiser and two other IQWiG employees involved in the early benefit assessment of the active substance palbociclib have drafted a letter to the editor to evaluate data from the PALOMA 2 study. 

They are surprised that on the one hand, the authors presented post-hoc analyses that were not foreseen in the study protocol, and on the other hand, they still did not present important data on the further course of the quality of life of women after the end of treatment.

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder